Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed creator / clinic practice
Attributed proposal / anecdote: Amount: 10 mg; Frequency: Once weekly; Route: Not documented; Population: Attributed creator / clinic practice
Limitations: Indirect transcript-index attribution. No native-MOTS-c human PK or dose-ranging trial validates this schedule; route and cycle length are not given.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed creator / clinic practice
Attributed proposal / anecdote: Amount: 5 mg; Frequency: Twice weekly; Route: Not documented; Population: Attributed creator / clinic practice
Limitations: Indirect transcript-index attribution. No native-MOTS-c human PK or dose-ranging trial validates this schedule; route and cycle length are not given.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Frequency: Brief higher-frequency “priming,” then return to one or two injections weekly; Duration: Short initiation phase; exact length not supplied; Route: Not documented
Limitations: The source does not define a priming amount or a fixed initiation frequency. Do not turn the warning about indefinite three-times-weekly use into a validated loading schedule.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Duration: 30 days; Route: Not documented; Sequence: After a reported six-week SS-31 course and before a reported one-month SS-31 course
Limitations: Amount, frequency, route and washout periods are not stated. Subjective response does not validate sequence superiority.
Limitations: A creator heuristic, not a demonstrated prerequisite or controlled sequence. Amounts, routes, phase lengths and washouts are not supplied.
Distinct protocol, timing or sequence preserved from the saved research material. Unreported fields remain unknown.
Context: Attributed research context; population or formulation not fully specified.
Attributed proposal / anecdote: Amount: 5 mg; Frequency: Three times weekly; Route: Not documented
Limitations: Author-reported community schedule, not a validated treatment regimen or personal recommendation. Cycling, rotation and adjunct superiority are not established. Missing fields are not inferred.
MOTS-c nominated in silico as a candidate Ms4a6c modulator in radiation proctitis (2026)
A 2026 computational study linked Ms4a6c+ macrophages to fibrosis in mouse radiation proctitis and, by virtual screening and molecular dynamics, nominated MOTS-c as the top candidate ligand for Ms4a6c. MOTS-c was not tested experimentally.
Context: Mouse transcriptomics and in silico screening only.
Limitations: Computational prediction only; docking score moderate-to-weak; no MOTS-c was administered.